Short answer: retatrutide (LY3437943) is not licensed as a medicine in the UK - it is still in Phase 3 trials - so no UK pharmacy or clinic can legally supply it. UK buyers can only access retatrutide from research-compound suppliers that label the material research use only, not for human consumption, ship on a tracked UK service, and provide a per-batch Certificate of Analysis with HPLC purity and mass-spec identity. New-U Research Compounds ships retatrutide (catalogued as GLP-1 RC-R) to UK addresses on a tracked service, with free delivery over £300.
“Where can I buy retatrutide in the UK?” is one of the fastest-growing peptide search queries of 2026, driven by Eli Lilly’s Phase 2 SURMOUNT-style data showing a mean weight reduction of roughly 24% over 48 weeks at the highest dose - the largest body-composition effect ever recorded in an incretin-class trial. The catch for UK buyers is straightforward: retatrutide has no marketing authorisation anywhere in the world, so it is not a prescription medicine and cannot be obtained from a UK pharmacy. This guide explains exactly what UK researchers can do, what compliant suppliers look like, and how the MHRA framing applies. For the wider legal picture, see our companion piece Are Peptides Legal in the UK?.
Plain-English summary. Retatrutide is an unapproved investigational peptide. UK law treats it as a research compound, not a medicine. You can lawfully purchase it for laboratory research provided the supplier makes no human-use claims, labels it research use only, and issues a Certificate of Analysis. This page is general information, not legal or medical advice; do not use unapproved peptides on people.
Retatrutide, developmental code LY3437943, is a 39-amino acid synthetic peptide developed by Eli Lilly. It is the first triple-receptor agonist to reach late-stage clinical trials, simultaneously activating three incretin and metabolic pathways: GLP-1, GIP, and glucagon. The glucagon arm is the differentiator - it drives hepatic thermogenesis and increases energy expenditure, on top of the appetite-suppression and insulinotropic effects already established for GLP-1 and dual GLP-1/GIP agonists.
For UK researchers comparing the incretin class, the line-up looks like this:
| Compound | Mechanism | Status | UK MHRA status |
|---|---|---|---|
| Semaglutide (GLP-1 RC-S) | GLP-1 receptor agonist | Approved (Ozempic, Wegovy) | Licensed medicine (prescription only) |
| Tirzepatide (GLP-1 RC-T) | Dual GLP-1 / GIP agonist | Approved (Mounjaro) | Licensed medicine (prescription only) |
| Retatrutide (GLP-1 RC-R, LY3437943) | Triple GLP-1 / GIP / glucagon agonist | Phase 3 trials, no approval | Not licensed - research compound only |
This is the key point UK buyers miss: retatrutide is a different regulatory category from Ozempic or Mounjaro. The first two are MHRA-licensed medicines. Retatrutide is not. That is why your GP cannot prescribe it, your local Boots or Lloyds cannot dispense it, and no UK private weight-loss clinic can supply it on a script. The only lawful UK route is research-use sourcing. For a side-by-side science explainer of the GLP-1 / GIP comparator class, see GLP-1 RC-S vs GLP-1 RC-T; for where retatrutide sits in the broader regulatory map of approved-vs-investigational peptides, see Peptides & the FDA.
The Medicines and Healthcare products Regulatory Agency (MHRA) regulates products presented for human or therapeutic use. A peptide marketed for people to take is treated as a medicine and must be licensed. A peptide supplied as a labelled research reagent - research use only, not for human consumption - is a separate, non-human-use category outside the MHRA medicines framework.
Because retatrutide has no marketing authorisation, the only thing the MHRA explicitly prohibits is selling or promoting it for human use. Possession of the molecule for genuine laboratory research is lawful. The legal line, exactly as for BPC-157 and the other research compounds covered in our UK legal explainer, is drawn at intended use and how the product is marketed, not at the molecule itself.
UK pharmacies and clinics can only dispense medicines that hold either a UK marketing authorisation or are imported under a named-patient / unlicensed-medicines special. Retatrutide has neither. Any UK-facing site claiming to sell “prescription retatrutide” or “clinic-grade retatrutide for weight loss” is either mis-selling a research compound under medical framing (which moves it into unlicensed-medicine territory the MHRA does prohibit), counterfeiting another GLP-1 product, or both. Treat any such offer as a red flag.
The bar for a research-compound supplier is documentation, not marketing. A UK-facing supplier you can rely on for retatrutide should tick all of the following:
The absence of any single one of those is enough to walk away. The absence of a per-batch CoA is disqualifying full stop - without it you have no way to verify the molecule is actually retatrutide and not a relabelled cheaper peptide.
On our catalogue, retatrutide is listed under the research-compound code GLP-1 RC-R. Same 39-amino acid sequence, same triple-agonist mechanism, same molecule that Eli Lilly studies as LY3437943 - the “RC-R” code is the research-compound naming convention we use for our incretin range (RC-S for semaglutide, RC-T for tirzepatide, RC-R for retatrutide). This is the SEO line where UK searches for “retatrutide UK” and catalogue listings labelled GLP-1 RC-R meet.
Research-compound retatrutide is sold per vial or per sealed 10-vial pack, with pricing scaling by the milligrams of peptide per vial. As a rough orientation only, expect a range broadly comparable to other Phase-3 incretin research peptides at the same purity grade: lower-mg tiers (5–10 mg) at the entry of the range, mid-tier (15–30 mg) in the middle, and high-mg tiers (40–60 mg) at the top. UK visitors see GBP totals at the cart - not a USD price “converted at checkout” with a hidden margin baked in.
Anyone quoting you a price well below the prevailing market for verified >99%-pure peptide should set off alarm bells: either the purity isn’t there, the CoA isn’t real, or the molecule isn’t retatrutide. For why purity is the only number that matters, see how to read a CoA and our broader how to buy research peptides walkthrough.
We dispatch UK orders on a tracked service with delivery typically inside the working week. The package is plain - no branding, no compound name on the outer label - and contains the sealed vials, a CoA reference card, and standard handling guidance. Because the contents are lyophilised research compound rather than a medicine, there is no controlled-drugs paperwork; the import is a normal scientific-reagent consignment.
Shipping is £25 flat tracked on UK orders, and free over £300 - which most retatrutide orders clear on the lowest tier. We absorb any minor handling fees up to the doorstep; on the rare occasion HMRC raises a query, we provide invoice and CoA documentation to support the research-reagent classification. See our UK delivery guide for the full breakdown.
The combination of high search demand and no licensed product creates a predictable scam surface. Walk away from any UK-facing retatrutide listing that:
Worth saying plainly: New-U does not sell pre-mixed or ready-to-inject retatrutide, does not sell “weight-loss-grade” retatrutide, does not provide pens, autoinjectors or human dosing kits, and does not provide any clinical protocol or dosing schedule for retatrutide. The catalogue listing is lyophilised research peptide in a sealed glass vial, period. Anyone in the UK selling retatrutide pens or pre-mixed solutions is operating outside the research-use framing - which is exactly what the MHRA prohibits.
If you are searching for “where to buy retatrutide UK”, the honest map looks like this: retatrutide is not a medicine in Britain, no UK pharmacy can sell it, and the only lawful route is a research-compound supplier that ships to the UK with the right documentation. The legality follows the framing - research reagent yes, unlicensed medicine no. Pick a supplier on the documentation (per-batch CoA, >99% HPLC, named lab, verifiable entity) rather than on the marketing copy. For anything health-related, consult a qualified clinician.
Is retatrutide legal to buy in the UK?
Yes for research purposes. Retatrutide is not MHRA-licensed and cannot be sold for human use; it can lawfully be purchased as a research compound provided the supplier labels it research use only and makes no human-use claims.
Where can I buy retatrutide in the UK?
No UK pharmacy or clinic can legally sell it. UK buyers source it from research-compound suppliers that ship to the UK, provide a per-batch CoA, and label material research use only. New-U ships retatrutide (catalogued as GLP-1 RC-R) on a tracked UK service.
How is retatrutide different from Ozempic or Mounjaro?
Ozempic (semaglutide) is GLP-1 only. Mounjaro (tirzepatide) is dual GLP-1 / GIP. Retatrutide (LY3437943) is triple GLP-1 / GIP / glucagon, with the glucagon arm adding hepatic thermogenesis. Retatrutide is the only one of the three that is unlicensed.
How much does retatrutide cost in the UK?
It is priced per vial in GBP, scaling by mg per vial across tiers from 5 mg to 60 mg. UK delivery is £25 tracked, free over £300.
How do I verify purity?
Demand a per-batch Certificate of Analysis showing HPLC purity (>99% is the credible standard) and mass-spec identity, from a named third-party lab such as Janoshik or Freedom Diagnostics. New-U publishes both.
External links are provided for research reference only; New-U is not affiliated with these organisations and links carry no endorsement either way.
New-U Research Compounds ships retatrutide (catalogued as GLP-1 RC-R) to UK addresses in sealed 10-vial packs, independently verified by Janoshik and Freedom Diagnostics for >99% purity, with a per-batch Certificate of Analysis. Tracked UK delivery, free over £300. Research use only - not for human consumption.
View GLP-1 RC-R (retatrutide)